|Bid||144.10 x N/A|
|Ask||144.64 x N/A|
|Day's range||144.03 - 145.27|
|52-week range||110.60 - 157.57|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
President Donald Trump’s recovery from COVID-19—and his aggressive advocacy of antibody cocktails as a “cure”—offer few reasons of encouragement for the general public given their relative scarcity, costs and mostly unproven nature, according to several experts who spoke to Yahoo Finance.
Pfizer seeks emergency use authorization in November despite anticipating results of its COVID-19 vaccine in October.